Tirzepatide as Adjunct to Insulin in Adults With Type 1 Diabetes and Overweight or Obesity: A Systematic Review of Randomized and Real‐World Evidence

Key Points

• The research aims to evaluate the effectiveness of tirzepatide as an adjunct treatment in adults with type 1 diabetes and obesity.
• Systematic review of randomized trials and real-world evidence
• Focus on weight reduction and glycaemic control
• Assessment of long-term safety
• Tirzepatide shows potential for weight reduction in adults with T1D and obesity.
• Current evidence does not support sustained glycaemic benefits.
• Need for larger trials to evaluate long-term safety and efficacy.